pre-seed
Stage
1
Investors
About
Peptimimesis is a French biotech company developing a new generation of peptide-based drugs. They use a proprietary technology platform to design cell-penetrating peptides that inhibit intracellular protein-protein interactions, primarily for oncology applications.
Explore Peptimimesis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.